Erowid References Database
|
Cavanagh RL, Tilson HA, Gylys JA.
“Neurochemical Properties of Dimoxamine (D), A New Psycho- therapeutic Agent”.
Pharmacologist. 1977;19(2):222.
|
|
Abstract
The differences in behavioral effects between dimoxamine (D) [BL-3912A; R-2-amino-i-(2,5-dimethoxy-4-methylphenyl) butane] and R-DOM in the rat have been described (Tilson et al., Psychopharmacol., 51:169, 1977). In the present study, the effects of D on brain biogenic amines were compared to those of d-LSD and R-DOM in the rat. D (20 or 40 mg/kg, i.p.) and R-DOM (5 or 15 mg/kg, i.p.) slightly decreased (10-20%) steady state levels and enhanced the turnover of norepinephrine and dopamine in discrete areas of the brain. D (20 mg/kg i.p.) increased steady state levels of serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) in the neocortex while in the diencephalon-limbic forebrain and hindbrain, it decreased 5-HT and elevated 5-HIAA. In contrast, R-DOM (5 Or 15 mg/kg, i.p.) increased both 5-HT and 5-HIAA levels and d-LSD (0.5 or 1 mg/kg, i.p.) elevated 5-HT and lowered 5-HIAA levels in all 3 brain areas. Results utilizing the isolated rat fundus strip, a preparation which is sensitive to 5-HT (ED50 mcg/ml, 0.005), indicated that R-DOM had potent 5-HT like agonist activity (ED50 mcg/ml, 0.033) while d-LSD acted as a 5-HT antagonist. D was a weak agonist (ED50 mcg/ml, 20.8) but also antagonized 5-HT and R-DOM induced spasms. Thus, with regard to effects on the serotonergic system of the rat, D could be differentiated from R-DOM and d-LSD.
|
| # |
| Submit Comment |
|
[
Cite HTML ]
